The Blueprint is intended to guide programming, resource allocation, and commitments to achieve the national objective of a contraceptive prevalence rate (CPR) of 36 percent by 2018.
PLOS ONE | www.plosone.org
September 2014 | Volume 9 | Issue 9 | e103657
2nd edition.
Like the original, this second edition of the guidance aims to inform the revision of existing national guidelines and standards for managing Tuberculosis (TB), many of which include guidance on children. It includes recommendations, based on the best available evidence, for improving ...the management of children with TB and of children living in families with TB. National and regional TB control programmes may wish to adapt these recommendations according to local circumstances
more
Journal des anthropologues n° 138-139, 2014
http://journals.openedition.org/jda/4444
Le médicament pharmaceutique industriel est un objet de santé
à la fois scientifique, populaire et marchand. Si ces deux premiers
caractères sont souvent mis en avant respectivement par les sciences
biom...édicales et pharmaceutiques, par la santé publique ainsi qu’à
travers les médias, sa troisième composante est plus souvent passée
sous silence. Elle tend à être dissimulée derrière ce qui est présenté
comme la vocation première du médicament, à savoir la santé des
individus, leur bien-être physique et psychique. Or, le caractère
marchand du médicament est un formidable vecteur de dynamiques
et d’initiatives. Il est peut-être ce qui explique avant tout
l’incroyable vitalité du secteur pharmaceutique de par la planète,
non sans poser de nombreux problèmes d’ordre sanitaire et de santé
publique.
more
International Journal of Infectious Diseases 32 (2015) 170–178
http://dx.doi.org/10.1016/j.ijid.2014.11.023
1201-9712/ß 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:...//creativecommons.org/licenses/by-nc-nd/3.0/).
more
Evaluation report
September 2014
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva...nt partners in their discussions to identify the best approaches to ensure the accelerated evaluation and use of available or near-term therapies and vaccines for the treatment and prevention of EVD. The document calls for a coordinated effort by the international community to remove unnecessary obstacles towards this goal.
more
An Independent Report
of the West Africa Commission on Drugs
One of the most important ways we feel we can help to reduce the burden of cancer in Africa is to work with African cancer advocacy organisations to help educate and advocate about cancer in their countries. To this end in 2010 we designed with our partners, 13 posters for use in Africa
giving heal...th and lifestyle tips on how to avoid cancer and highlighting the early warning sign and symptoms of common cancers in Africa
more